Patents Assigned to ACCUTAR BIOTECHNOLOGY INC.
  • Publication number: 20240059698
    Abstract: Disclosed are heteroaryl compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 22, 2024
    Applicant: Accutar Biotechnology Inc.
    Inventors: Jie FAN, Yimin QIAN, Wei HE, Ke LIU, Pin HUANG, Xiangyan SUN, Jie SU, Ji LIU
  • Publication number: 20240051940
    Abstract: The disclosure provides sulfonamides based compounds and pharmaceutical compositions thereof, which are useful for inhibiting one or more mutations of EGFR, as well as methods for using such compounds to treat cancer associated with EGFR mutations.
    Type: Application
    Filed: February 7, 2022
    Publication date: February 15, 2024
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Yimin QIAN, Robert LUO, Wei HE, Jie Fan
  • Publication number: 20230150973
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Application
    Filed: June 27, 2022
    Publication date: May 18, 2023
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin QIAN, Wei HE, Ke LIU
  • Publication number: 20230135173
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Application
    Filed: October 24, 2022
    Publication date: May 4, 2023
    Applicant: Accutar Biotechnology Inc.
    Inventors: Jie FAN, Yimin Qian, Wei He, Ke Liu
  • Patent number: 11535606
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: December 27, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Patent number: 11530222
    Abstract: The present disclosure relates to novel compounds of Formula (I) that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.
    Type: Grant
    Filed: February 2, 2022
    Date of Patent: December 20, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Yimin Qian, Wei He, Robert Luo, Jie Su, Hui Zhang, Ke Liu, Jie Fan
  • Patent number: 11521712
    Abstract: A computer-implemented method for predicting a conformation of a ligand docked into a protein is disclosed. According to some embodiments, the method may include determining one or more poses of the ligand in the protein, the poses being representative conformations of the ligand. The method may also include determining, using a neural network, energy scores of the poses. The method may further include determining a proper conformation for the docked ligand based on the energy scores.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: December 6, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Ke Liu, Sun Xiangyan
  • Patent number: 11420956
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: August 23, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Publication number: 20220259207
    Abstract: The present disclosure relates to novel compounds that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.
    Type: Application
    Filed: February 2, 2022
    Publication date: August 18, 2022
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Yimin Qian, Wei He, Robert Luo, JIE SU, HUI ZHANG, KE LIU, JIE FAN
  • Publication number: 20220238191
    Abstract: The present disclosure provides methods and apparatuses for molecular modeling with machine-learned universal potential functions. An exemplary method includes: determining a data structure representing chemical identities of atoms in a molecule; training an energy potential model using a training set comprising the data structure, true conformations of the molecule, and false conformations of the molecule; determining, using the trained energy potential model, a potential function associated with the molecule; or determining a conformation of the molecule based on potential function.
    Type: Application
    Filed: January 28, 2022
    Publication date: July 28, 2022
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Ke LIU, Xiangyan SUN
  • Publication number: 20220220124
    Abstract: Compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and other related diseases and conditions are disclosed.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 14, 2022
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Wei HE, Ke LIU
  • Patent number: 11312702
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: April 26, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Publication number: 20220112204
    Abstract: The present disclosure relates to novel compounds that inhibit KRAS G120, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin QIAN, Wei HE, Robert Z. LUO
  • Patent number: 11261178
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: March 1, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Patent number: 11220490
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: January 11, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Publication number: 20210300901
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Application
    Filed: May 26, 2021
    Publication date: September 30, 2021
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin QIAN, Wei HE, Ke LIU
  • Patent number: 11117885
    Abstract: The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 14, 2021
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Ke Liu, Hui Zhang, Wei He
  • Publication number: 20210246449
    Abstract: The present disclosure relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that prevent or reduce exon 8 skipping in the SLC26A4 gene during pre-mRNA splicing, and their use in the treatment of Pendred Syndrome.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 12, 2021
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventor: Yimin HUA
  • Publication number: 20210221802
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
    Type: Application
    Filed: June 22, 2020
    Publication date: July 22, 2021
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin Qian, Wei He, Ke Liu
  • Patent number: 10968212
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: April 6, 2021
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Ke Liu